BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Mylan Inc. (MYL) Tries to Get Its Hands on Ranbaxy Laboratories (RANBAXY.BO)' Rights Over Novartis AG (NVS)'s Diovan


12/7/2012 7:54:04 AM

The Swiss drug maker Novartis had been bracing all year for the day in late September when Diovan, its top-selling blood pressure drug, would lose patent protection and a cheaper generic version would become available. But September has come and gone, and now, nearly three months later, there is still no generic alternative to Diovan on the market. The Food and Drug Administration has not given final clearance to Ranbaxy, the generic drug maker that won the exclusive right to sell the drug for the first six months after its patent expired. Now a competing generic company, Mylan, is suing the F.D.A. to force the agency to revoke Ranbaxy’s exclusive rights and allow Mylan to begin selling the drug. A hearing on the matter is scheduled for Friday in federal court in Washington. Mylan is exclusively selling a related drug, a combination of Diovan and a diuretic, whose patent protection also expired in September. The delay in approval of generic Diovan has proved to be an unexpected bright spot for Novartis, since Diovan brought in more than $1.9 billion in United States sales last year, according to the health care research firm IMS Health. “It’s like extra cash,” said Kim Vukhac, an analyst for Crédit Agricole.

Read at New York Times

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->